Psychotic Disorder Clinical Trial
— MACS-RCTOfficial title:
Mobile After-Care Support Intervention for Patients With Schizophrenia Following Hospitalization: Pilot RCT
Verified date | February 2024 |
Source | Butler Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The overall aim of this program of research is to refine and test the feasibility and acceptability of a newly developed mobile device-delivered app, called Mobile After-Care Support (MACS), to improve patients' coping and treatment adherence following a hospitalization related to their psychotic-spectrum disorder. The purpose of the proposed project is to establish the feasibility, acceptability, and preliminary effects of the app. To achieve the specific aims, the investigators will conduct a pilot randomized clinical trial (n = 60), with two treatment arms: MACS vs. a mobile app attention control condition.
Status | Completed |
Enrollment | 42 |
Est. completion date | May 31, 2022 |
Est. primary completion date | May 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - recently hospitalized - DSM-5 criteria for psychotic-spectrum disorder based on structured clinical interview - 18 years or older - prescribed antipsychotic medication upon discharge - ability to speak and read English Exclusion Criteria: - substance use disorders at severe level - planned discharge to supervised living setting or participation in formal outpatient adherence programs - pregnancy or other medical condition contraindicating use of antipsychotic medications |
Country | Name | City | State |
---|---|---|---|
United States | Butler Hospital | Providence | Rhode Island |
Lead Sponsor | Collaborator |
---|---|
Butler Hospital | National Institute of Mental Health (NIMH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Client Satisfaction Questionnaire (CSQ) | The Client Satisfaction Questionnaire is a self-report measure of patient satisfaction with treatment. The total score (sum of items) will be used and ranges from 8 to 32 with increased scores indicating greater satisfaction with treatment. | 1 month | |
Secondary | Brief Psychiatric Rating Scale (BPRS) | The interviewer-rated Brief Psychiatric Rating Scale is a measure of psychiatric symptom severity. The total score (sum of items) will be used to assess overall severity with scores ranging from 18 to 126 and higher scores indicating greater severity. | Baseline, 4 month | |
Secondary | Brief Adherence Rating Scale (BARS) | The Brief Adherence Rating Scale assesses the percentage of missed medication doses over the past month. The total adherence score ranges from 0% to 100% and higher scores indicate greater adherence. | Baseline, 4 month | |
Secondary | Brief Cope Inventory (Brief COPE) | The Brief Cope Inventory is a 28 item self-report measure of coping skills. The mean values of the 12-item dysfunctional coping subscale was used. Mean scores for the total range from 1-48 with higher scores indicating greater use of the dysfunctional coping strategies. | Baseline, 4 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02306551 -
Well Being And Resilience: Mechanisms of Transmission of Health and Risk
|
||
Active, not recruiting |
NCT00627029 -
Evaluation of Programs of Coordinated Care and Disease Management
|
N/A | |
Terminated |
NCT00049738 -
Screening for Childhood-Onset Psychotic Disorders
|
N/A | |
Withdrawn |
NCT01724372 -
The Role of Antidepressants or Antipsychotics in Preventing Psychosis
|
N/A | |
Completed |
NCT00716755 -
Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.
|
N/A | |
Completed |
NCT00498550 -
Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual
|
Phase 4 | |
Terminated |
NCT04140773 -
The Effect of D-serine as add-on Therapy in Recent-onset Psychosis
|
N/A | |
Completed |
NCT01473550 -
Mental Health Engagement Network (MHEN)
|
N/A | |
Completed |
NCT01207219 -
Yoga and Aerobic Exercise in Psychosis
|
N/A | |
Completed |
NCT00397033 -
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
|
Phase 3 | |
Recruiting |
NCT04945278 -
Study of Self-Recognition and Self/Other Distinction Disorders in Patients With Psychological Vulnerability
|
N/A | |
Completed |
NCT00287352 -
Study of Amantadine for Weight Stabilization During Olanzapine Treatment
|
Phase 1 | |
Completed |
NCT00005658 -
Glycine to Treat Psychotic Disorders in Children
|
Phase 2 | |
Terminated |
NCT00169026 -
Alcoholism and Schizophrenia: Effects of Clozapine
|
Phase 4 | |
Completed |
NCT00001482 -
New Drugs in the Treatment of Mood Disorders
|
Phase 2 | |
Terminated |
NCT03671005 -
Mindfulness-based Group Therapy for Inpatients With Schizophrenia Spectrum Disorders
|
N/A | |
Completed |
NCT00156715 -
Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
|
Phase 4 | |
Completed |
NCT00095524 -
Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
|
Phase 3 | |
Completed |
NCT03667729 -
The Effects of Progressive Muscle Relaxation Therapy in Patients With Schizophrenia
|
N/A | |
Completed |
NCT00001656 -
Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
|
Phase 4 |